StreetInsider.com News Articles

Form 8-K Eton Pharmaceuticals, For: Oct 14

Wed, 14 Oct 2026 07:15:00 -0400

si-local-file:///var/storage/secattach/20261014/27183612.html

Eton and Aquestive strike U.S. deal for diazepam buccal film

Wed, 14 Oct 2026 06:51:35 -0400

Eton Pharmaceuticals (Nasdaq: ETON) and Aquestive Therapeutics (Nasdaq: AQST) have entered into an exclusive U.S. licensing and supply agreement for Libervant (diazepam) buccal film, a treatment for seizure clusters in epilepsy patients, according to a joint press release dated Oct. 14, 2026.

Under the agreement, Eton receives exclusive U.S. commercialization rights to Libervant, a buccal film that dissolves inside the cheek without a delivery device. The product carries Orphan Drug Designation and has tentative FDA approval for patients ages 2 to 5 and 12 and older. A separate application to expand the label to include patients ages 6 to 11 carries

Eton and Aquestive strike U.S. deal for diazepam buccal film

Wed, 14 Oct 2026 06:51:35 -0400

Eton and Aquestive strike U.S. deal for diazepam buccal film

Wed, 14 Oct 2026 06:51:35 -0400

Eton and Aquestive strike U.S. deal for diazepam buccal film

Wed, 14 Oct 2026 06:51:35 -0400

Eton Pharmaceuticals and Aquestive Therapeutics Announce Exclusive U.S. Licensing Agreement for LIBERVANT® (diazepam) Buccal Film

Wed, 14 Oct 2026 06:50:00 -0400

Differentiated, portable buccal film would offer patients and caregivers an alternative to existing nasal and rectal seizure rescue treatments, a market opportunity that exceeds $450 million annually in the U.S.
Patient market research demonstrated strong preference for buccal film, with 71% of surveyed patients preferring film versus 13% for nasal spray, assuming equivalent efficacy
Anticipated commercial launch in April 2027, subject to final FDA approval, provides a potential near-term growth opportunity and new commercial platform in neurology
LIBERVANT has received Orphan Drug Designation and has issued patent protection extending into 2038, with additional patent applications pending with the U.S. Patent and Trademark

Eton Pharmaceuticals and Aquestive Therapeutics Announce Exclusive U.S. Licensing Agreement for LIBERVANT® (diazepam) Buccal Film

Wed, 14 Oct 2026 06:50:00 -0400

Differentiated, portable buccal film would offer patients and caregivers an alternative to existing nasal and rectal seizure rescue treatments, a market opportunity that exceeds $450 million annually in the U.S.
Patient market research demonstrated strong preference for buccal film, with 71% of surveyed patients preferring film versus 13% for nasal spray, assuming equivalent efficacy
Anticipated commercial launch in April 2027, subject to final FDA approval, provides a potential near-term growth opportunity and new commercial platform in neurology
LIBERVANT has received Orphan Drug Designation and has issued patent protection extending into 2038, with additional patent applications pending with the U.S. Patent and Trademark

Eton Pharmaceuticals and Aquestive Therapeutics Announce Exclusive U.S. Licensing Agreement for LIBERVANT® (diazepam) Buccal Film

Wed, 14 Oct 2026 06:50:00 -0400

Differentiated, portable buccal film would offer patients and caregivers an alternative to existing nasal and rectal seizure rescue treatments, a market opportunity that exceeds $450 million annually in the U.S.
Patient market research demonstrated strong preference for buccal film, with 71% of surveyed patients preferring film versus 13% for nasal spray, assuming equivalent efficacy
Anticipated commercial launch in April 2027, subject to final FDA approval, provides a potential near-term growth opportunity and new commercial platform in neurology
LIBERVANT has received Orphan Drug Designation and has issued patent protection extending into 2038, with additional patent applications pending with the U.S. Patent and Trademark

Eton Pharmaceuticals and Aquestive Therapeutics Announce Exclusive U.S. Licensing Agreement for LIBERVANT® (diazepam) Buccal Film

Wed, 14 Oct 2026 06:50:00 -0400

Differentiated, portable buccal film would offer patients and caregivers an alternative to existing nasal and rectal seizure rescue treatments, a market opportunity that exceeds $450 million annually in the U.S.
Patient market research demonstrated strong preference for buccal film, with 71% of surveyed patients preferring film versus 13% for nasal spray, assuming equivalent efficacy
Anticipated commercial launch in April 2027, subject to final FDA approval, provides a potential near-term growth opportunity and new commercial platform in neurology
LIBERVANT has received Orphan Drug Designation and has issued patent protection extending into 2038, with additional patent applications pending with the U.S. Patent and Trademark

Form 4 Eton Pharmaceuticals, For: Oct 06 Filed by: Krempa David

Tue, 06 Oct 2026 16:49:00 -0400

si-local-file:///var/storage/secattach/20261006/27156128.html

Form 144 Eton Pharmaceuticals, Filed by: Krempa David

Tue, 06 Oct 2026 16:05:00 -0400

si-local-file:///var/storage/secattach/20261006/27155469.html

Form 8-K Eton Pharmaceuticals, For: Sep 28

Mon, 28 Sep 2026 07:15:00 -0400

si-local-file:///var/storage/secattach/20260928/27110006.html

Eton Pharmaceuticals launches Impavido capsules in the U.S.

Mon, 28 Sep 2026 06:51:22 -0400

Eton Pharmaceuticals (Nasdaq: ETON) announced the commercial launch of Impavido (miltefosine) capsules in the United States, with the company holding exclusive commercialization rights for the drug.

Impavido is an antileishmanial drug indicated for adults and adolescents 12 years of age and older weighing at least 30 kg for the treatment of visceral, cutaneous, and mucosal leishmaniasis caused by specific Leishmania species.

Distribution is centralized through Anovo Specialty Pharmacy, which is intended to support outpatient prescribing, inpatient consignment, and urgent access coordination. Clinicians can e-prescribe by selecting Anovo #5 (Memphis) or submit a patient referral form by fax.

Eton has also integrated its Eton

Eton Pharmaceuticals Announces U.S. Commercial Availability of IMPAVIDO® (miltefosine) Capsules

Mon, 28 Sep 2026 06:50:00 -0400

Eton Pharmaceuticals now holds exclusive commercialization rights for IMPAVIDO in the United States
Eton has integrated full Eton Cares^® patient support, including $0 co-pay for eligible commercially insured patients and expanded patient assistance programs
Centralized distribution through Anovo Specialty Pharmacy is designed to simplify access and therapy initiation for outpatient prescribing, inpatient consignment, and urgent access coordination

DEER PARK, Ill., Sept. 28, 2026 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or “the Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced

Eton Pharmaceuticals Announces U.S. Commercial Availability of IMPAVIDO® (miltefosine) Capsules

Mon, 28 Sep 2026 06:50:00 -0400

Eton Pharmaceuticals now holds exclusive commercialization rights for IMPAVIDO in the United States
Eton has integrated full Eton Cares^® patient support, including $0 co-pay for eligible commercially insured patients and expanded patient assistance programs
Centralized distribution through Anovo Specialty Pharmacy is designed to simplify access and therapy initiation for outpatient prescribing, inpatient consignment, and urgent access coordination

Form 4 Eton Pharmaceuticals, For: Aug 28 Filed by: MAIER PAUL V

Fri, 28 Aug 2026 16:51:00 -0400

si-local-file:///var/storage/secattach/20260828/26998791.html

Form 4 Eton Pharmaceuticals, For: Aug 28 Filed by: MAIER PAUL V

Fri, 28 Aug 2026 16:51:00 -0400

si-local-file:///var/storage/secattach/20260828/26998791.html

Form 144 Eton Pharmaceuticals, Filed by: MAIER PAUL V

Fri, 28 Aug 2026 16:41:00 -0400

si-local-file:///var/storage/secattach/20260828/26998684.html

Form 144 Eton Pharmaceuticals, Filed by: MAIER PAUL V

Fri, 28 Aug 2026 16:41:00 -0400

si-local-file:///var/storage/secattach/20260828/26998684.html

Eton Pharmaceuticals to Participate at 2026 Wells Fargo Healthcare Conference

Thu, 27 Aug 2026 06:50:00 -0400

DEER PARK, Ill., Aug. 27, 2026 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or the “Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that members of the Company’s executive leadership team will host 1x1 meetings on September 9, 2026 at the 2026 Wells Fargo Healthcare Conference being held September 8-10, 2026 in Boston, MA.

To schedule a 1x1 meeting with the Company, please contact your Wells Fargo institutional sales representative.

About Eton Pharmaceuticals

Eton is an innovative pharmaceutical company focused on developing and commercializing treatments

Eton Pharmaceuticals to Participate at 2026 Wells Fargo Healthcare Conference

Thu, 27 Aug 2026 06:50:00 -0400

To schedule a 1x1 meeting with the Company, please contact your Wells Fargo institutional sales representative.

About Eton Pharmaceuticals

Eton is an innovative pharmaceutical company focused on developing and commercializing treatments

Form 4 Eton Pharmaceuticals, For: Aug 24 Filed by: Krempa David

Mon, 24 Aug 2026 17:20:00 -0400

si-local-file:///var/storage/secattach/20260824/26969165.html

Form 4 Eton Pharmaceuticals, For: Aug 24 Filed by: Krempa David

Mon, 24 Aug 2026 17:20:00 -0400

si-local-file:///var/storage/secattach/20260824/26969165.html

Form 144 Eton Pharmaceuticals, Filed by: Krempa David

Mon, 24 Aug 2026 16:20:00 -0400

si-local-file:///var/storage/secattach/20260824/26968364.html

Form 144 Eton Pharmaceuticals, Filed by: Krempa David

Mon, 24 Aug 2026 16:20:00 -0400

si-local-file:///var/storage/secattach/20260824/26968364.html